ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,867.08
      -0.09%
      US Tech 100
      20,566.80
      0.00%
      Dow Jones
      42,342.24
      0.04%
      Brent Oil
      72.205
      -0.25%
      Bitcoin
      96,738.30
      -0.74%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Canada
      5. NEO

      6. Abbvie CDR (ABBV) Quote

      Abbvie CDR

      Abbvie CDR (ABBV)

      AbbVie Inc
      24.78
      -0.22
      (-0.88%)
      Closed December 20 4:00PM
      Realtime Data

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      24.78
      Bid
      23.84
      Ask
      27.08
      Volume
      30,670
      24.65 Day's Range 25.15
      0.00 52 Week Range 0.00
      Previous Close
      25.00
      Open
      25.15
      Last Trade
      100
      @
      24.78
      Last Trade Time
      Average Volume (3m)
      -
      Financial Volume
      -
      VWAP
      -

      Ask ADVFN Intelligence (AI)

      ABBV Latest News

      More News

      Form 4 - Statement of changes in beneficial ownership of securities

      December 18 2024
      Edgar (US Regulatory)

      Form 144 - Report of proposed sale of securities

      December 16 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      December 13 2024
      Edgar (US Regulatory)

      AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline

      AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline PR Newswire NORTH CHICAGO, Ill. and MADISON, Wis., Dec. 13, 2024 Proposed acquisition adds Nimble's lead asset, an...

      December 13 2024
      PR Newswire (US)

      AbbVie Completes Acquisition of Aliada Therapeutics

      AbbVie Completes Acquisition of Aliada Therapeutics PR Newswire NORTH CHICAGO, Ill., Dec. 11, 2024 Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease...

      December 11 2024
      PR Newswire (US)

      Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma

      Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell...

      December 09 2024
      PR Newswire (US)

      AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease

      AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease PR Newswire NORTH CHICAGO, Ill., Dec. 9, 2024 Tavapadon met...

      December 09 2024
      PR Newswire (US)

      AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients

      AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients PR Newswire NORTH CHICAGO, Ill., Dec. 8, 2024 -New insights show Black, Hispanic, and Asian...

      December 08 2024
      PR Newswire (US)

      Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

      Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) PR...

      December 07 2024
      PR Newswire (US)

      AbbVie to Present at Citi's 2024 Global Healthcare Conference

      AbbVie to Present at Citi's 2024 Global Healthcare Conference PR Newswire NORTH CHICAGO, Ill., Nov. 25, 2024 NORTH CHICAGO, Ill., Nov. 25, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will...

      November 25 2024
      PR Newswire (US)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10000000DR
      40000000DR
      120000000DR
      260000000DR
      520000000DR
      1560000000DR
      2600000000DR

      ABBV - Frequently Asked Questions (FAQ)

      What is the current Abbvie CDR share price?
      The current share price of Abbvie CDR is $ 24.78
      What is the 1 year trading range for Abbvie CDR share price?
      Abbvie CDR has traded in the range of $ 0.00 to $ 0.00 during the past year

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      HOLDImmutable Holdings Inc
      $ 0.14
      (27.27%)
      		10.9k
      INXDINX Digital Company Inc
      $ 0.08
      (14.29%)
      		202.6k
      DMETDenarius Metals Corp
      $ 0.61
      (5.17%)
      		3.8k
      JETGlobal Crossing Airlines Group Inc
      $ 0.65
      (1.56%)
      		7.5k
      BCBNBase Carbon Inc
      $ 0.395
      (1.28%)
      		196.18k
      TILTTILT Holdings Inc
      $ 0.005
      (-50.00%)
      		90k
      JPEGPioneer Media Holdings Inc
      $ 0.01
      (-33.33%)
      		8k
      GRAMGold Flora Corporation
      $ 0.015
      (-25.00%)
      		1.65M
      BMNDBiomind Labs Inc
      $ 0.365
      (-21.51%)
      		500
      MLMMcfarlane Lake Mining Limited
      $ 0.02
      (-20.00%)
      		265.68k
      DEFIValour Inc
      $ 3.62
      (-8.35%)
      		2M
      BTQBTQ Technologies Corp
      $ 2.87
      (-18.93%)
      		2M
      VERSVerses AI Inc
      $ 1.05
      (-10.26%)
      		1.67M
      GRAMGold Flora Corporation
      $ 0.015
      (-25.00%)
      		1.65M
      CBSTCannabist Company Holdings Inc
      $ 0.075
      (0.00%)
      		787.86k

      Discussion

      View Full Feed
      236T568 236T568 3 minutes ago
      Very Sad

      David Gergen, Adviser To 4 U.S. Presidents, Has Dementia

      https://www.huffpost.com/entry/david-gergen-dementia_n_67647dd6e4b00aa16adf512f
      rikkie rikkie 4 minutes ago
      Look at Polariton and AMF! They have produced world class products in speed, consumption and size. Look at the patents LWLG has collected in photonics and polymers. Don't tell me this will just disappear. I remain optimistic about the polymer "perkinamine" and have higher expectations now that Yves
      LWLG
      fuagf fuagf 5 minutes ago
      My take on all of that is unchanged from the time i arrived in 1967. Australia, like every other country, has bigoted people whether the bigotry is based on ethnicity, imagined race or religion. The antipathy against Israel now is more based on the genocidal posture of the country toward Palesti
      Banjo50 Banjo50 15 minutes ago
      BIG LOTS FOLDING THE TENT! TOLD YOU SO! COMPLETELY MISMANAGED FOR THE LASR FIVE YEARS!!!
      BIGGQ
      IVRT IVRT 19 minutes ago
      I think the last BMXI carrot is Hall Cadwick. There is no other reason to delay. Cannot replace Hall because the ladder does not go any higher up. The delays have become a millstone around BMXI's neck. Either as you say the audit is fictitious or the audit must be done in January. There are no
      BMXI
      chereb19 chereb19 34 minutes ago
      Isopet has been proven to be profitable
      RDGL
      QuantumTravesty QuantumTravesty 37 minutes ago
      Thanks.
      HIRU
      knrorrel knrorrel 53 minutes ago
      very nice
      QNCCF
      GASMASK GASMASK 1 hour ago
      What's/who's TA?
      MRGE
      JerryCampbell JerryCampbell 1 hour ago
      Data entry error the previous day.

      Someone mistakenly entered 8,000,000 instead of 800,000. The -7.2m corrects it.
      NWBO
      georgejjl georgejjl 1 hour ago
      I guess that Anavex could have sales of $14 billion during the first full year after approval in 2026 by the EMA in the EU alone based on capturing a 25% market share of the 8 million people in the EU with Alzheimer’s disease at a prescription cost of $7,000 per year per patient.

      Go
      AVXL
      jeunke22 jeunke22 1 hour ago
      Thanks KCC , I am still very positive about my investment here. Doing business implies to understand when it is time to adapt to a given set of circumstances. No need to try to go through a wall, if you can go around it. I think that is what has changed here. A more practical and energetic way to g
      LWLG
      DMC8 DMC8 1 hour ago
      Feeling burnout recently fellow shareholders?

      Watch the youtube chat on how to manage burnout by Patrice Bonfiglio, President of Sarissa Capital Management LP.
      https://youtu.be/wpFutxLn-wk?si=6Rm2JhCbHvgvUcsb
      AMRN
      lodas lodas 1 hour ago
      jhdf51........never buy a Put or a Call option unless you are 100% sure of the outcome at expiration.... why? you only a 50% chance of success... said another way... you either win, or lose...... however by Selling a Put, or Call options, you have a 66% chance of winning, or 2 ways out of three...
      COOP
      pepeoil pepeoil 1 hour ago
      Good morning shrimpers. Bwahaaaaaa. We are broke. Lol
      THEDOG 17 THEDOG 17 2 hours ago
      O and you may as well clock out because Bio was acquired!! Yeah if you can’t figure it out maybe you should read that report eagle just posted!!!! Acquisition!!!!! Let’s gooo
      jhdf51 jhdf51 2 hours ago
      My bird in the hand is COOP. Escrow is now a ROC
      capable of carrying hopeful escrowers in its talons.

      JHD
      COOP
      jhdf51 jhdf51 2 hours ago
      It seems that people playing options are like people going to Vegas.. they never lose.

      JHD
      COOP
      2018trader 2018trader 2 hours ago
      Just keep buying the monopoly 7, I mean mag 7
      SPY
      TCI1 TCI1 2 hours ago
      I can’t open the link to the CVS coverage for 2025, would like to see it as they dropped Vascepa in July.

      Sleven have you seen any positive or negative changes?
      CVS
      TCI1 TCI1 2 hours ago
      Well UHC has both IPE and Vascepa covered with PA so you would hope and expect all CVD indications to go to Vascepa. Not sure if this is a change or not but by using a PA UHC are exposing themselves to litigation if they prioritise generic for CVD. Of course this is based off insurers adhering to th
      AMRN
      Real McCoy Real McCoy 2 hours ago
      Yes. In this case the assets were acquired. A long time ago. Right?
      THEDOG 17 THEDOG 17 2 hours ago
      Sorry I can read !! Obviously you can’t. Acquisition-is that not a real word?
      devil dog 96 devil dog 96 2 hours ago
      Their O/S has been unchanged since 2021. These guys protect their share structure + they are great at marketing. Can't wait for them to be ready to fire up their next story. She is setup for some silver with how light they have kept her. Heck she has not had an RS since 2009 like 16 years ago and sh
      CRSM

      Your Recent History

      NEO
      ABBV
      Abbvie CDR
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads